\
&
Contact us
\
&
Contact us
Starts in 3 weeks from now
LocationOnline
ProgrammesThe European Partnership for Personalised Medicine has just launched a new opportunity for start-ups, researchers and early-stage teams working on cutting-edge solutions in personalised medicine.
EP PerMed Fast Track Validation Programme has been designed to address a key challenge in the development of personalised medicine (PM) solutions: the validation phase. Transitioning innovative concepts into market-ready products requires thorough validation to ensure they align with the needs and expectations of end-users, including clinicians and patients.
The Fast Track Validation Programme provides a structured and accelerated pathway for PM innovators to successfully validate their solutions. In this webinar, EP PerMed will offer an overview of the programme, its requirements, and the application and support process, providing key insights for those interested in applying.
More information and registration here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security AI, data & cloud Cybersecurity Defence Space
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
